Dong Quai (Angelica sinensis) in the treatment of hot flashes for men on androgen deprivation therapy: results of a randomized double-blind placebo controlled trial
Al-Bareeq RJ, Ray AA, Nott L, Pautler SE, Razvi H
Published in Canadian Urological Association Journal
Methodology
Randomised, double-blind, placebo-controlled trial of daily Dong Quai versus placebo for 3 months in 22 men on LHRH agonist therapy for prostate cancer with bothersome hot flashes, tracking daily vasomotor logs, PSA and coagulation parameters
Key Findings
Dong Quai did not significantly reduce hot flash frequency, duration or severity compared with placebo.
Conclusions
A well-controlled trial found no vasomotor benefit, consistent with the negative postmenopausal literature.
Limitations
Small sample; male androgen-deprivation population rather than menopausal women; short duration.
Supplements Studied
A randomized double-blind placebo controlled trial was conducted involving 22 men receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer with bothersome hot flashes.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Not reported
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.